Clearside Biomedical Inc. (NASDAQ:CLSD) announced promising Cohort 1 OASIS study results of CLS-AX. Six patients with neovascular age-related macular degeneration received CLS-AX through suprachoroidal injection using the company’s SCS Microinjector. The phase1/2a study achieved primary endpoints with the lowest planned 0.03 mg CLS-AX dose tolerated well without adverse events, and no treatment-related adverse events were observed during the study.
The company indicated that the average participant age in Cohort 1 was 82 years. Also, all patients had undergone prior anti-VEGF treatment through several standard-of-care injections before the commencement of the OASIS trial. Equally, participants underwent diagnostic imaging during screening before the masked reading center for persistent active disease confirmation. Following a review of the trial data, the safety monitoring committee has confirmed that CLS-AX will advance into Cohort 2.
Clearside Biomedical will commence Cohort 2 patient screening with a dose of 0.1 mg CLS-AX this month, and completion of the trial period will commence by the end of 2021. With these positive results, CLSD is a stock to watch.